Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sangamo Biosciences (SGMO) and Athenex (ATNX).
Sangamo Biosciences (SGMO)
Wedbush analyst Liana Moussatos reiterated a Hold rating on Sangamo Biosciences today and set a price target of $12.00. The company’s shares closed last Wednesday at $10.23.
According to TipRanks.com, Moussatos is a 5-star analyst with an average return of 12.1% and a 54.4% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.
Currently, the analyst consensus on Sangamo Biosciences is a Hold with an average price target of $12.00.
See today’s analyst top recommended stocks >>
Athenex (ATNX)
In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Athenex, with a price target of $23.00. The company’s shares closed last Wednesday at $12.13.
According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 35.3% and a 56.0% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, Rocket Pharmaceuticals, and Cellectar Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Athenex with a $24.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.